BCAL Diagnostics Pty Ltd Australia

BCAL Diagnostics is a Sydney, Australia based blood diagnostics company with research facilities based in Kentucky, USA.

The BCAL lipid biomarker test is a universal blood test for the effective screening and monitoring of breast cancer.  The BCAL test is being developed to be safe, cost effective, accurate and available to all women regardless of age, race and geographic location.

BCAL Diagnostics is near completion of a 200-patient study. Initial results indicate the BCAL test has a greater than 90% sensitivity and specificity in the diagnosis of invasive ductal carcinoma which is 85% of all breast cancers. 

This will lead to a range of BCAL breast cancer blood tests that can be used across the full breast cancer disease management continuum. from pre-disposition to screening to long term monitoring.

BCAL Diagnostics is now seeking Series B capital of $5-$10M USD to support its global commercialisation activities.

Year Founded
2010
Biotech Subsector
Medtech Subsector
Medtech Phase of Development
Technology Overview
Breast Cancer Associated Lipids
Alliance & Collaborations
Research agreements with Kentucky University USA and Royal Prince Alfred Hospital - NSW Australia
Supporting Metrics or Evidence
80 patient study completed - 200 patient study near completion
Current Financing Needs
$5-$10M Series B
Current Investors
small number of highly sophisticated investors
IP Status
Strong - patents pending
Recent Milestones
Completed 100 sample study with 90% sensitivity and specificity results for the detection of invasive ductal carcinoma
Management Team Highlights
CEO has global diagnostic experience with Roche Diagnostics, Boehringer Mannheim and Cochlear. Management team has extensive lipids in cancer experience with published papers and PhD
Philip Daffas
LinkedIn logo CEO 
BIO

 

Phiilip Daffas is the CEO  of BCAL Diagnostics Pty Ltd a Sydney based diagnostics company. With a career spanning more than 25 years, he brings a wealth of experience in global sales, marketing and business development in the medical devices and diagnostics market. 

 Philip has been based in Sydney since 2001 and has held senior global business leadership positions in Europe, US and Australia with blue chip healthcare companies. He has been instrumental in building businesses, growing market share and developing extensive high-level customer and industry relationships in each sector.

 Roles in Australia have included VP Global Marketing at Cochlear and General Management roles with Roche Diagnostics and Bio-Rad Laboratories and CEO of Applied Physiology, an Australian start up company in the intensive care monitoring sector.

Philip’s earlier experience was gained in Europe with market leaders such as IVAC infusion systems and Shiley cardiopulmonary products. He subsequently joined Boehringer Mannheim, initially in the UK managing their diagnostics business and subsequently was promoted to Global Marketing Director for the Diabetes Care business based in Mannheim, Germany.

In 1997 Philip joined Cochlear in the UK as the European Sales and Marketing Manager and subsequently was promoted to the VP Global Marketing role based in Sydney, Australia.

Graduated in the UK with a BSc and Diploma in Electronic Engineering, Philip also holds an MBA and is a Graduate of the Australian Institute of Company Directors (GAICD).


Peter French
Director & Scientific Advisor 
Dharmica Mistry
Scientific Officer 

Bionic Vision Technologies Australia

Bionic Vision Technologies is the commercial entity which holds license to the patents around technology developed by Bionic Vision Australia.

Bionic Vision Australia brings together Australia’s leading experts in medical bionics to develop a bionic eye to restore vision to people with retinitis pigmentosa and age-related macular degeneration.  A prototype device has been successfully implanted into three patients for two years demonstrating outstanding safety and efficacy. 

Our capabilities which  differentiate us from competitors include:

  1. Novel surgical techniques providing greater safety and stability od wide view devices

  2. World leading, pioneering vision processing software

  3. Unique arrangement and stimulation strategies of the electrodes

  4. Unique diamond electrode encapsulation for the high acuity device

  5. World leading psychophysics laboratory for assessing functionality of the devices

  6. Unprecedented expertise and proven track record in preclinical studies

Our development portfolio consists of  wide view devices which aim to increase mobility and independence of patients and a high acuity device which will allow patients the ability to read large letters and recognise faces

Year Founded
2011
Main Sector
Medtech Phase of Development
IP Status
7 granted patents, 45 patent applications
Recent Milestones
Completed successful pilot clinical trial
Julia Hill

BioScience Managers Australia

BioScience Managers is a venture capital life science investment firm headquartered in Melbourne, Australia. The group makes equity investments from $3M-5M and anticipates about 6 new investments this year. BioScience Managers invests globally. 

BioScience Managers will invest in companies across the life science space, including therapeutics, diagnostics and medical technology. The group does not invest in service providers. BioScience Managers considers all subsectors and indications, including orphan indications. The group will consider technology either in or prepared for human clinical trials and is open to all classes of devices. BioScience Managers seeks investments in novel technology and is not looking to gain share of an existing market. 

Investor Type
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Jeremy Curnock Cook
Managing Director 
Amanda Gillon
Investment Analyst 
Matt McNamara
CIO 

Medifruit Pty Ltd Australia

We are an Australian Biotechnology Company nearing completion on five year R&D programme into new, novel compounds from natural rare Australian extracts for both the prophylactic and treatment of giardiasis.

Current R&D programmes in both Australia and Boston, MA.

World’s first alternative natural treatment to antibiotic strength drugs of choice against bacteria and protozoa for animals envisages enormous market potential, including human, organic, veterinary and husbandry sectors   

Fast kill rate ‘within 5 minutes’  

Non-Toxic and safe for human and animal consumption.

No antibiotic resistance problems that plague current treatment modalities [due to multiple compounds]

Kills all the life cycle – Pluripotent and treats both the disease and the pathogenesis of the disease in multiple ways

MOA established and known [several]

Website:
TBA
Year Founded
2012
Biotech Subsector
Biotech Phase of Development
Technology Overview
Giardia
Current Financing Needs
seed angel to $1 million
Current Investors
Private
Giles Tilley
Director